Press Releases
For more information, contact: Angela deGravelles at 225-202-5073 or email prpro@eatel.net with your questions or comments.
The Pennington Biomedical Research Center will be issued a patent for a new cancer treatment that will fight the most common forms – prostate, breast, ovarian and testicular cancer. This new treatment has killed cancerous tumors on laboratory mice while leaving normal cells unaffected. The treatment also destroys mestacized cells which spreads throughout the body and eventually results in death.
According to Pennington research experts, it is difficult to predict exactly when clinicals trials would start, if the drug makes it to that level; perhaps 1 to 3 years. When the drug would be available on a large scale is also difficult to predict. If research is funded, the drug passes all lab and clinical trials and is approved by the FDA, 10 to 12 years is a reasonable estimate.
Please check back for more information.
Pennington Patent Makes National News
Released: Tuesday, October 21, 2003The Pennington Biomedical Research Center will be issued a patent for a new cancer treatment that will fight the most common forms – prostate, breast, ovarian and testicular cancer. This new treatment has killed cancerous tumors on laboratory mice while leaving normal cells unaffected. The treatment also destroys mestacized cells which spreads throughout the body and eventually results in death.
According to Pennington research experts, it is difficult to predict exactly when clinicals trials would start, if the drug makes it to that level; perhaps 1 to 3 years. When the drug would be available on a large scale is also difficult to predict. If research is funded, the drug passes all lab and clinical trials and is approved by the FDA, 10 to 12 years is a reasonable estimate.
Please check back for more information.
